|
Dr. Jeffrey Besterman brings nearly 20 years of corporate and academic drug discovery experience to the GNS advisory board. Since joining MethylGene in 1997, he established and supervises all R&D activities at the drug design company, which focuses on the inhibition of quality enzyme targets associated with disease. Prior to MethylGene, Dr. Besterman worked at the Glaxo Research Institute in Research Triangle Park, first as head of the Oncology Research Section and later as head of the Department of Cell Biology. Dr. Besterman received a B.Sc. in biology from the State University of New York, Stony Brook, and a Ph.D. in physiology and biophysics from the University of Vermont School of Medicine. | 